Document Detail


Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors.
MedLine Citation:
PMID:  22536933     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Romidepsin is a potent histone deacetylase inhibitor; preclinical studies showed potential synergy with the nucleoside analog gemcitabine. This phase 1 trial was conducted to determine the maximum tolerated dose for two schedules of romidepsin plus gemcitabine in patients with advanced solid tumors in which gemcitabine had previously demonstrated clinical activity. The recommended phase 2 dose was 12 mg/m(2) romidepsin plus 800 mg/m(2) gemcitabine on days 1 and 15 every 28 days. Results suggest additive hematologic toxicities of romidepsin plus gemcitabine, but the level of antitumor activity observed warrants more formal trials of this combination to further assess safety and efficacy.
Authors:
Suzanne F Jones; Jeffrey R Infante; David R Spigel; Nancy W Peacock; Dana S Thompson; F Anthony Greco; William McCulloch; Howard A Burris
Related Documents :
3023553 - Twenty-four hour changes in active and inactive renin after various oral doses of the c...
7151873 - Centrally mediated enhancement of ouabain cardiotoxicity by angiotensin ii in dogs.
7310323 - Reference values of renal excretion of fluoride.
Publication Detail:
Type:  Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-04-26
Journal Detail:
Title:  Cancer investigation     Volume:  30     ISSN:  1532-4192     ISO Abbreviation:  Cancer Invest.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-05-31     Completed Date:  2012-07-27     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  8307154     Medline TA:  Cancer Invest     Country:  England    
Other Details:
Languages:  eng     Pagination:  481-6     Citation Subset:  IM    
Affiliation:
Sarah Cannon Research Institute, Nashville, TN 37203, USA. suzanne.jones@scresearch.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Deoxycytidine / administration & dosage,  analogs & derivatives*
Depsipeptides / administration & dosage*
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms / drug therapy*
Chemical
Reg. No./Substance:
0/Depsipeptides; 128517-07-7/romidepsin; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stressors and sources of support: the perceptions and experiences of newly diagnosed Latino youth li...
Next Document:  TNF-? Expression in the UCB-MSCs as Stable Source Inhibits Gastric Cancers Growth in Nude Mice.